BOSTON, Sept 12- Billionaire investor Carl Icahn, a born New Yorker who has run his business from the city for decades, is moving his office, more than half of his staff and himself to Florida early next year, people familiar with the plan said on Thursday. The 83- year-old investor, known for picking winners and facing off with captains of industry, has grown weary of...
June 25- Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection. But it now faces competition from cheaper versions in Europe and a 2023...
June 25- Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection. But it now faces competition from cheaper versions in Europe and a 2023...
June 25- Drugmaker AbbVie Inc said on Tuesday it would buy Botox-maker Allergan Plc for about $63 billion, grabbing control of by far the biggest name in medical aesthetics to help reduce its reliance on blockbuster arthritis treatment Humira. AbbVie has been under pressure to diversify its portfolio as Humira, the world's best-selling drug, is already in...
June 25- Drugmaker AbbVie Inc said on Tuesday it would buy Botox-maker Allergan Plc for about $63 billion, grabbing control of by far the biggest name in medical aesthetics to help reduce its reliance on blockbuster arthritis treatment Humira. Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each share held, for a total...
Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each share held, for a total value of $188.24 per Allergan share.
NEW YORK, May 1- Allergan Plc shareholders have voted down a nonbinding proposal that sought an immediate split of the roles of chairman and chief executive, with 61.3 percent of shareholders backing Chairman and CEO Brent Saunders. Billionaire investor David Tepper's hedge fund Appaloosa LP made the proposal, arguing that drugmaker Allergan currently has a...
April 15- Two major shareholder advisory firms urged investors to vote against billionaire investor David Tepper's hedge fund demand that Allergan Plc immediately split the roles of chief executive officer and chairman, in a boost to the Botox maker. The recommendation from Institutional Shareholder Services LP and Glass Lewis& Co against the proposal of...
April 15- Allergan Plc said on Monday that proxy advisory firms Institutional Shareholder Services Inc and Glass Lewis& Co had urged its shareholders to vote against hedge fund Appaloosa Plc's proposal to immediately separate the drugmaker's chief executive officer and chairman roles. Appaloosa, led by billionaire David Tepper, has been pressing Allergan...
March 25- Activist investor Appaloosa LP said on Monday that Allergan Plc's board was doing "everything except what needs to be done" in a series of concessions the drug company announced last week in response to criticism from the hedge fund. A source close to Allergan told Reuters on Friday that current Chairman and CEO Brent Saunders, 49, has no plans to step...
Allergan said its experimental add-on treatment for depression failed three late-stage studies, casting doubts over its drugs pipeline.
CNBC's Leslie Picker follows the money and reports on Appaloosa's David Tepper as he submits his letter to shareholders upping the pressure on Allergan.
The hedge fund manager recommends that the drug company jump-start the business with new strategies.
PG&E's stock added to its abysmal three-month slide Tuesday as the former hedge fund favorite prepares for bankruptcy.
Last week's big sell-off and Monday's stock drop presented an opportunity, the hedge fund manager tells CNBC.
Hedge fund titan David Tepper says the Federal Reserve is sending the market a message, and it's not a good one.
U.S. stocks swooned again on Thursday after the Fed raised interest rates and said that it would continue to let its balance sheet shrink
David Tepper's Appaloosa Management sold its Apple position after the end of the third quarter, according to sources familiar with the matter.
CNBC's Scott Wapner reports that Appaloosa Management founder David Tepper is no longer long Apple. Trader Jim Lebenthal weighs in.
Billionaire manager David Tepper's firm had added 100,000 shares of Apple and 1.2 million shares of financial firm State Street by the end of September.
Data also provided by 
